Based on these findings, we conclude that pan-EGFR inhibitor (canertinib or afatinib) will specifically down regulate EGFR and HER2 and result in an anti-proliferative effect in pancreatic cancer cells. The gene discussed is ERBB2; the disease is pancreatic neoplasm.